Nausea tends to intensify during the first one to two weeks of the new dose, then progressively improves
Under the brand name Zepbound, it's approved to treat obesity, while under the brand name Mounjaro, it's approved to treat type 2 diabetes
Here are the most common ones: Nausea: This is the most common side effect, especially when starting the medication
Semaglutide was selected for Medicare drug price negotiation in 2025, with a negotiated price set to take effect in 2027 but that negotiated price applies to diabetes and cardiovascular indications covered under current Medicare statute, not to obesity, which remains statutorily excluded
Following guidance from your healthcare provider and slowly increasing your dose could help to reduce these side effects
How GLP-1 for Binge Eating Affect the ADHD Brain As a nutritional therapist specialising in ADHD, I see a significant overlap between neurodivergence and binge eating, read more about it here